The UK pharma sector expects one of its biggest challenges to be the risk of incurring fines as they establish in emerging economies, according to research by MindMetre Research and commissioned by life science consultancy firm Maetrics.
The study surveyed more than 50 compliance and quality management professionals from life sciences sectors including pharma, medical device biology and nutrition. Participants came from both large companies and small-to-medium enterprises to determine the industry outlook and examine growth drivers.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze